<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2243">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943618</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0850</org_study_id>
    <secondary_id>R01DA024709-01A1</secondary_id>
    <secondary_id>NCI-2011-01101</secondary_id>
    <nct_id>NCT00943618</nct_id>
  </id_info>
  <brief_title>Combining Varenicline and Bupropion for Smoking Cessation</brief_title>
  <official_title>Effectiveness of Varenicline vs. Varenicline Plus Bupropion or Placebo for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is learn if the combination of Chantix (varenicline)&#xD;
      and Zyban (bupropion) is more effective at helping people to quit smoking than varenicline&#xD;
      when given alone. Researchers also want to learn if this drug combination can reduce cravings&#xD;
      and other negative symptoms of nicotine withdrawal better than varenicline does alone. The&#xD;
      safety of this drug combination will also be tested.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Bupropion and varenicline are designed to imitate the effects that nicotine has on the body.&#xD;
      This may reduce cigarette cravings and help patients quit smoking.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the roll of a dice) to 1 of 3 treatment groups.&#xD;
&#xD;
        -  If you are in Group 1, you will receive varenicline and bupropion.&#xD;
&#xD;
        -  If you are in Group 2, you will receive varenicline and a placebo. A placebo is a&#xD;
           substance that looks like the study drug (in this case, bupropion) but that has no&#xD;
           active ingredients.&#xD;
&#xD;
        -  If you are in Group 3, you will receive a placebo that looks like varenicline and a&#xD;
           placebo that looks like bupropion.&#xD;
&#xD;
      You will have a higher chance (5 out of 6) of receiving study drug than receiving just&#xD;
      placebo. Equal numbers of patients will be in Groups 1 and 2. Neither you nor the study&#xD;
      doctor will know to which group you are assigned. However, if needed for your safety, the&#xD;
      study staff will be able to find out which study drug you are receiving.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will begin taking the study drugs/placebo 1 to 10 days after the first study visit. A&#xD;
      dose of the study drug/placebo combination will be made up of 1 tablet of varenicline or&#xD;
      placebo and 1 tablet of bupropion or placebo. You should take each dose of study&#xD;
      drugs/placebo with a cup (8 oz.) of water after eating a full meal.&#xD;
&#xD;
      On Days 1-3, you will take 1 dose of the study drug/placebo combination in the morning.&#xD;
&#xD;
      Beginning on Day 4, and then every day after that, you will take 1 dose in the morning and 1&#xD;
      dose in the evening (for a total of 2 doses of the study drug/placebo combination each day).&#xD;
      You must return any study drug bottles as well as any unused study drug to a study staff&#xD;
      member at each study visit.&#xD;
&#xD;
      You will be given a smoking diary to record how many cigarettes you smoke (if any) each day&#xD;
      while you are on study. You must turn in this diary at each study visit.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      About 1 time each week while you are taking the study drugs/placebo, the following tests and&#xD;
      procedures will be performed:&#xD;
&#xD;
        -  Your weight and blood pressure will be measured.&#xD;
&#xD;
        -  Your CO level will be measured.&#xD;
&#xD;
        -  You will be asked about any other drugs you may be taking and about any side effects you&#xD;
           may be having.&#xD;
&#xD;
        -  You will answer 8 questionnaires about several topics, including depression, suicide,&#xD;
           your smoking behavior, any effects from the study drugs, and any symptoms of&#xD;
           attention-deficit hyperactivity disorder (ADHD). These should take about 30-45 minutes&#xD;
           total to complete.&#xD;
&#xD;
        -  You will do tasks that will measure your logic and attention. These will take about 15&#xD;
           -20 minutes to complete.&#xD;
&#xD;
        -  You will receive counseling about quitting smoking in which you discuss possible&#xD;
           &quot;triggers&quot; for smoking and strategies for dealing with quitting smoking. These sessions&#xD;
           will take about 15 minutes each time.&#xD;
&#xD;
      During counseling at the first study visit, you will set a &quot;quit date&quot; for stopping smoking&#xD;
      for about 1 week after you start taking the study drug. You should not quit smoking before&#xD;
      the quit date. You should stay smoke-free after the quit date. Additionally, you will be&#xD;
      given a medication instruction sheet, a card with emergency contact information, and a&#xD;
      participant manual to help you follow along with the topics discussed during counseling.&#xD;
&#xD;
      At Week 2, saliva will be collected to check your cotinine level.&#xD;
&#xD;
      At Week 4, blood (about 2 teaspoons) will be drawn to assess liver and kidney function.&#xD;
&#xD;
      Lab Sessions:&#xD;
&#xD;
      You may be asked to take part in lab sessions during Visits 1, 2, and 6 to test your brain&#xD;
      activity and attention span. You will be asked to watch slides and listen to a series of&#xD;
      tones. The slides will include pictures of people, nature, and artwork. Slides showing nude&#xD;
      people, medical procedures, and victims of car crashes will also be shown. You will be shown&#xD;
      examples of these slides before beginning the procedure and given the opportunity to withdraw&#xD;
      from the study.&#xD;
&#xD;
      During the lab sessions, your brain electrical activity (EEG) will be monitored. To do this,&#xD;
      small sensors will be placed on your scalp and face. You should not drink more than 2 cups of&#xD;
      coffee or other caffeinated drinks for at least 2.5 hours before each session. At the first&#xD;
      lab session, you may be asked to smoke a cigarette if the doctor thinks it is needed for you&#xD;
      to exhibit your normal smoking behavior.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will receive the study drug for up to 12 weeks. However, the entire length of the study&#xD;
      is about 13 months (55 weeks), which includes 3, 6, and 12-month post-quit follow up visits.&#xD;
      You will be taken off study if the doctor thinks it is in your best interest.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      After you have finished taking the study drugs/placebo, the following tests and procedures&#xD;
      will be performed:&#xD;
&#xD;
        -  Your weight and blood pressure will be measured.&#xD;
&#xD;
        -  Your CO level will be measured.&#xD;
&#xD;
        -  You will be asked about any side effects you may be having and about any other drugs you&#xD;
           may be taking.&#xD;
&#xD;
        -  Blood (about 2 teaspoons) will be drawn to assess liver and kidney function.&#xD;
&#xD;
        -  You will answer the same questionnaires you completed at the regular study visits. These&#xD;
           should take about 30-45 minutes total to complete.&#xD;
&#xD;
        -  Saliva will be collected to measure your cotinine level.&#xD;
&#xD;
      Follow-Up Visits:&#xD;
&#xD;
      About 3, 6, and 12 months after you have stopped smoking, the following tests and procedures&#xD;
      will be performed:&#xD;
&#xD;
        -  Your weight, heart rate, and blood pressure will be measured.&#xD;
&#xD;
        -  Your CO level will be measured.&#xD;
&#xD;
        -  You will be asked about any side effects you may be having and about any other drugs you&#xD;
           may be taking.&#xD;
&#xD;
        -  You will answer the same questionnaires you completed at the regular study visits. These&#xD;
           should take about 30-45 minutes total to complete.&#xD;
&#xD;
        -  Saliva will be collected to measure your cotinine level.&#xD;
&#xD;
      You will be called by the study staff 1 day before your quit date, 3 days after your quit&#xD;
      date, and at Weeks 14, 20, 34, 42, and 48 weeks after your quit date to check on your&#xD;
      progress in quitting smoking. Each call should take about 10-15 minutes.&#xD;
&#xD;
      This is an investigational study. Varenicline and bupropion are both FDA approved and&#xD;
      commercially available to help people stop smoking. The use of the drugs in combination is&#xD;
      investigational.&#xD;
&#xD;
      Up to 385 participants will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2010</start_date>
  <completion_date type="Actual">September 9, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Smoking Abstinence at 12 Months</measure>
    <time_frame>From quit date to 12 months.</time_frame>
    <description>Prolonged Abstinence is defined as no smoking from the quit date to 12 Months post quit date.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">641</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Varenicline and Bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Varenicline and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo that looks like varenicline and a placebo that looks like bupropion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Counseling/Phone Calls</intervention_name>
    <description>Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 25-70 years old&#xD;
&#xD;
          2. Smoking 5 or more cigarettes per day, on average, within the 2 months preceding the&#xD;
             screening visit and expired CO of greater than or equal to 6ppm.&#xD;
&#xD;
          3. Able to follow verbal and written instructions in English and complete all aspects of&#xD;
             the study&#xD;
&#xD;
          4. Provide informed consent and agree to all assessments and study procedures&#xD;
&#xD;
          5. Have an address and home telephone number where they may be reached&#xD;
&#xD;
          6. Be the only participant in their household&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Within the month immediately preceding the screening visit, use of any form of tobacco&#xD;
             products other than cigarettes on 3 or more days within a week if the individual&#xD;
             refuses to refrain from such tobacco use during the course of the study.&#xD;
&#xD;
          2. Within the month immediately preceding the screening visit, use of marijuana in any&#xD;
             form on 3 or more days within a week&#xD;
&#xD;
          3. Within the two weeks immediately preceding the screening visit, involvement on more&#xD;
             than 3 days in any formal smoking cessation activities&#xD;
&#xD;
          4. Treatment on a continuous basis within 2 weeks before the screening visit: any&#xD;
             contraindicated medication for Varenicline or Bupropion. Classes of contraindicated&#xD;
             medications include, but are not limited to, antiasthmatics, antipsychotics, some&#xD;
             antidepressants, antihypertensives, antiarrhythmics, antineoplastics, some&#xD;
             antiseizures, and MAO inhibitors (See Appendix U for specific list of excluded and&#xD;
             precautionary medications).&#xD;
&#xD;
          5. Uncontrolled hypertension (average reading of systolic blood pressure greater than 150&#xD;
             or diastolic blood pressure greater than 95) or other major contraindications for&#xD;
             Bupropion or Varenicline (See section on Screening).&#xD;
&#xD;
          6. Severe renal impairment (Creatinine Clearance less than 30 ml/min/1.73 m2).&#xD;
&#xD;
          7. Laboratory evaluations outside normal limits and of potential clinical significance in&#xD;
             the opinion of the investigator.&#xD;
&#xD;
          8. Meet current criteria for psychiatric disorders or substance abuse as assessed by the&#xD;
             MINI plus (major depressive episode) and the MINI for items B, D, I, J (Alcohol&#xD;
             Addendum-past 6 months only), K, L, M and N including a past manic or hypomanic&#xD;
             episode as well as a lifetime psychotic disorder.&#xD;
&#xD;
          9. Individuals rated as moderate (6 - 9) to high (10 or greater) on suicidality as&#xD;
             assessed by Module C of the MINI.&#xD;
&#xD;
         10. Psychiatric hospitalization within 1 year of screening date.&#xD;
&#xD;
         11. A positive urine pregnancy test during the screening period. Women who are two years&#xD;
             post menopausal, or who have had a tubal ligation or a partial or full hysterectomy&#xD;
             will not be subject to a urine pregnancy test.&#xD;
&#xD;
         12. Pregnant, breast-feeding or of childbearing potential and is not protected by a&#xD;
             medically acceptable, effective method of birth control while enrolled in the study.&#xD;
             Medically acceptable contraceptives include: (1) approved hormonal contraceptives&#xD;
             (such as birth control pills, patches, implants or injections), (2) barrier methods&#xD;
             (such as a condom or diaphragm) used with a spermicide, or (3) an intrauterine device&#xD;
             (IUD). Contraceptive measures sold for emergency use after unprotected sex, are not&#xD;
             acceptable methods for routine use.&#xD;
&#xD;
         13. Use of Varenicline or Bupropion within two weeks before the screening visit.&#xD;
&#xD;
         14. History of hypersensitivity or allergic reaction to Varenicline, tricyclic&#xD;
             antidepressant, Bupropion (Wellbutrin, Zyban) or similar chemical classes or any&#xD;
             component of these formulations.&#xD;
&#xD;
         15. Current or previous history of a seizure disorder.&#xD;
&#xD;
         16. Current or previous history of anorexia.&#xD;
&#xD;
         17. Subject considered by the investigator as unsuitable candidate for receipt of an&#xD;
             investigational drug or unstable to be followed up throughout the entire duration of&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M Cinciripini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <results_first_submitted>April 27, 2021</results_first_submitted>
  <results_first_submitted_qc>July 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Nicotine Withdrawal</keyword>
  <keyword>Smoking Reduction</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Chantix</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Zyban</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT00943618/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Paid and unpaid media advertising from May 2010 to July 2013 recruited volunteer smokers from the Houston, Texas metropolitan area. Inclusion criteria included: 25- 65 years of age; smoke five or more cigarettes per day (CPD); baseline expired carbon monoxide (CO) level greater than 6 parts per million (p.m.); fluent in English; stable residency.</recruitment_details>
      <pre_assignment_details>641 patients were consented to this study; 250 patients were screen failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline + Bupropion</title>
          <description>Smokers in varenicline + bupropion took 0.5 mg varenicline once per day for the first three days and 0.5 mg bid (am and pm) for the next 4 days. They also took 150 mg bupropion (SR once per day for the first 3 days followed by 150mg bid for the next 4 days. From week 2-12 smokers in the VB group will take 1mg of varenicline and one active 150 mg bupropion tablet twice per day.</description>
        </group>
        <group group_id="P2">
          <title>Varenicline</title>
          <description>Smokers in varenicline group took took 0.5 mg varenicline once per day for the first three days and 0.5 mg bid (am and pm) for the next 4 days. They also took a matching bupropion placebo on the same schedule as those in the varenicline + bupropion group. From week 2-12, smokers in the varenicline group took 1mg of varenicline and one bupropion matching placebo twice per day.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Smokers in the placebo group took a matching varenicline and bupropion placebos on the same schedule as the varenicline group took varenicline and the bupropion group took bupropion, respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued Medication</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis dataset is comprised of all treated participants, i.e. Intention to Treat.</population>
      <group_list>
        <group group_id="B1">
          <title>Varenicline + Bupropion</title>
          <description>Smokers in varenicline + bupropion took 0.5 mg varenicline once per day for the first three days and 0.5 mg bid (am and pm) for the next 4 days. They also took 150 mg bupropion (SR once per day for the first 3 days followed by 150mg bid for the next 4 days. From week 2-12 smokers in the VB group will take 1mg of varenicline and one active 150 mg bupropion tablet twice per day.</description>
        </group>
        <group group_id="B2">
          <title>Varenicline</title>
          <description>Smokers in varenicline group took took 0.5 mg varenicline once per day for the first three days and 0.5 mg bid (am and pm) for the next 4 days. They also took a matching bupropion placebo on the same schedule as those in the varenicline + bupropion group. From week 2-12, smokers in the varenicline group took 1mg of varenicline and one bupropion matching placebo twice per day.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Smokers in the placebo group took a matching varenicline and bupropion placebos on the same schedule as the varenicline group took varenicline and the bupropion group took bupropion, respectively.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="163"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="385"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.36" spread="9.38"/>
                    <measurement group_id="B2" value="48.75" spread="10.89"/>
                    <measurement group_id="B3" value="48.48" spread="10.33"/>
                    <measurement group_id="B4" value="48.97" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="340"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Married or Living with partner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.94"/>
                    <measurement group_id="B2" value="53.01"/>
                    <measurement group_id="B3" value="62.50"/>
                    <measurement group_id="B4" value="50.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.06"/>
                    <measurement group_id="B2" value="46.99"/>
                    <measurement group_id="B3" value="37.50"/>
                    <measurement group_id="B4" value="49.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment Status</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Employed/Student</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.72"/>
                    <measurement group_id="B2" value="80.72"/>
                    <measurement group_id="B3" value="78.57"/>
                    <measurement group_id="B4" value="81.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unemployed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.28"/>
                    <measurement group_id="B2" value="19.28"/>
                    <measurement group_id="B3" value="21.43"/>
                    <measurement group_id="B4" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depression History</title>
          <description>Depression history indicates whether the participant had a history of depression (positive) or did not have a history of depression (negative). It is a proportions/percentages characteristic.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years of education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.89" spread="2.11"/>
                    <measurement group_id="B2" value="13.60" spread="1.92"/>
                    <measurement group_id="B3" value="13.80" spread="1.89"/>
                    <measurement group_id="B4" value="13.75" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoking Rate</title>
          <units>cigs per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.64" spread="9.49"/>
                    <measurement group_id="B2" value="19.02" spread="9.49"/>
                    <measurement group_id="B3" value="19.71" spread="11.20"/>
                    <measurement group_id="B4" value="19.66" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous Quit Attempts</title>
          <units>Number of quit attempts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.58" spread="13.51"/>
                    <measurement group_id="B2" value="5.83" spread="9.22"/>
                    <measurement group_id="B3" value="6.12" spread="13.90"/>
                    <measurement group_id="B4" value="6.62" spread="11.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age started smoking</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.41" spread="5.15"/>
                    <measurement group_id="B2" value="18.16" spread="60.16"/>
                    <measurement group_id="B3" value="16.48" spread="3.43"/>
                    <measurement group_id="B4" value="18.02" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fagerström Test for Nicotine Dependence (FTND) Total Score</title>
          <description>FTND (Fagerström Test for Nicotine Dependence) SCORE (Range = 0-10) Higher scores indicate more dependence.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.74" spread="2.01"/>
                    <measurement group_id="B2" value="4.65" spread="2.04"/>
                    <measurement group_id="B3" value="5.34" spread="2.24"/>
                    <measurement group_id="B4" value="4.79" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Center for Epidemiologic Studies Depression Scale (CESD)</title>
          <description>CESD consists of twenty items that are rated on a four-point likert scale (from 1: rarely or none of the time to 4: most or all of the time). Scores range from zero to sixty. Higher scores indicated a higher frequency of depressive symptoms. CORE (Range = 0-60). Higher scores indicate more depression.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.82" spread="5.37"/>
                    <measurement group_id="B2" value="7.76" spread="7.07"/>
                    <measurement group_id="B3" value="6.59" spread="6.17"/>
                    <measurement group_id="B4" value="6.73" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS)</title>
          <description>The questionnaire contains 20 items on two subscales that assess a person's positive and negative trait affect using a 5-point scale (1= &quot;very slightly or not at all&quot;; 5=&quot; extremely&quot;). SCORE (Range 10-50). Higher scores in the PANAS Negative scale indicate higher negative emotions&quot;. &quot;Higher scores in the PANAS Positive scale indicate higher positive emotions</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>PANAS Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.56" spread="4.93"/>
                    <measurement group_id="B2" value="14.93" spread="5.31"/>
                    <measurement group_id="B3" value="14.44" spread="4.39"/>
                    <measurement group_id="B4" value="14.70" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANAS Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.08" spread="7.64"/>
                    <measurement group_id="B2" value="33.26" spread="7.43"/>
                    <measurement group_id="B3" value="33.84" spread="8.80"/>
                    <measurement group_id="B4" value="33.69" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wisconsin Smoking Withdrawal Scale (WSWS)</title>
          <description>Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. The items are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). SCORE (Range= 0-12). Higher scores in the Anger, Anxiety, Sadness, Craving and Hunger scale indicate worse outcome; higher scores in the Concentration indicates lack of concentration, higher score in sleep scale indicate more problems sleeping.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Anger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.57" spread="2.25"/>
                    <measurement group_id="B2" value="4.01" spread="2.48"/>
                    <measurement group_id="B3" value="3.67" spread="23.8"/>
                    <measurement group_id="B4" value="3.77" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.80" spread="2.74"/>
                    <measurement group_id="B2" value="6.96" spread="2.99"/>
                    <measurement group_id="B3" value="7.15" spread="2.76"/>
                    <measurement group_id="B4" value="6.92" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.80" spread="2.05"/>
                    <measurement group_id="B2" value="3.84" spread="2.02"/>
                    <measurement group_id="B3" value="3.69" spread="1.99"/>
                    <measurement group_id="B4" value="3.80" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.40" spread="2.63"/>
                    <measurement group_id="B2" value="9.86" spread="2.94"/>
                    <measurement group_id="B3" value="9.87" spread="2.85"/>
                    <measurement group_id="B4" value="9.67" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hunger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.67" spread="3.39"/>
                    <measurement group_id="B2" value="10.46" spread="3.50"/>
                    <measurement group_id="B3" value="10.31" spread="3.44"/>
                    <measurement group_id="B4" value="10.10" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sadness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.38" spread="2.21"/>
                    <measurement group_id="B2" value="4.76" spread="2.48"/>
                    <measurement group_id="B3" value="4.55" spread="2.04"/>
                    <measurement group_id="B4" value="4.57" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.91" spread="4.04"/>
                    <measurement group_id="B2" value="8.52" spread="4.48"/>
                    <measurement group_id="B3" value="8.16" spread="4.47"/>
                    <measurement group_id="B4" value="8.21" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wisconsin Index of Smoking Dependence Motives (WISDM)</title>
          <description>(WISDM) is comprised of 68 items designed to assess 13 different motivational domains: affiliative attachment, automaticity, loss of control, behavioral choice/melioration, cognitive enhancement, craving, cue exposure/associative processes, negative reinforcement, positive reinforcement, social/environmental goads, taste/sensory properties, tolerance, and weight control. The WISDM consists of 68 items that are rated on a 7-point Likert scale. SCORE (Range = 1-7). Subscales are summed to provide a total score (Range = 11-77). In all cases higher scores indicate worse outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>WISDM-Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.83" spread="2.00"/>
                    <measurement group_id="B2" value="4.75" spread="2.01"/>
                    <measurement group_id="B3" value="5.22" spread="1.97"/>
                    <measurement group_id="B4" value="4.85" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Affiliation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.20" spread="2.13"/>
                    <measurement group_id="B2" value="3.87" spread="2.22"/>
                    <measurement group_id="B3" value="4.41" spread="2.42"/>
                    <measurement group_id="B4" value="4.09" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Automaticity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.05" spread="2.02"/>
                    <measurement group_id="B2" value="5.57" spread="2.17"/>
                    <measurement group_id="B3" value="6.42" spread="2.11"/>
                    <measurement group_id="B4" value="5.90" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Cognitive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.66" spread="2.09"/>
                    <measurement group_id="B2" value="4.37" spread="2.17"/>
                    <measurement group_id="B3" value="4.82" spread="2.05"/>
                    <measurement group_id="B4" value="4.56" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.17" spread="1.73"/>
                    <measurement group_id="B2" value="6.32" spread="1.87"/>
                    <measurement group_id="B3" value="6.51" spread="2.09"/>
                    <measurement group_id="B4" value="6.28" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Craving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.11" spread="1.62"/>
                    <measurement group_id="B2" value="5.95" spread="1.78"/>
                    <measurement group_id="B3" value="6.53" spread="1.83"/>
                    <measurement group_id="B4" value="6.11" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Cue Exposure-Associative Processes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.36" spread="1.82"/>
                    <measurement group_id="B2" value="5.34" spread="2.02"/>
                    <measurement group_id="B3" value="5.56" spread="1.74"/>
                    <measurement group_id="B4" value="5.38" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Social-Environmental Goads</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.00" spread="2.22"/>
                    <measurement group_id="B2" value="3.77" spread="2.54"/>
                    <measurement group_id="B3" value="4.25" spread="2.59"/>
                    <measurement group_id="B4" value="3.94" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Primary Dependence Motives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.08" spread="1.53"/>
                    <measurement group_id="B2" value="5.96" spread="1.64"/>
                    <measurement group_id="B3" value="6.43" spread="1.75"/>
                    <measurement group_id="B4" value="6.08" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Secondary Dependence Motives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.57" spread="1.36"/>
                    <measurement group_id="B2" value="4.38" spread="1.48"/>
                    <measurement group_id="B3" value="4.71" spread="1.46"/>
                    <measurement group_id="B4" value="4.51" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Taste and Sensory Processes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.52" spread="2.06"/>
                    <measurement group_id="B2" value="5.29" spread="2.27"/>
                    <measurement group_id="B3" value="5.50" spread="2.11"/>
                    <measurement group_id="B4" value="5.41" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Tolerance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.01" spread="2.04"/>
                    <measurement group_id="B2" value="6.01" spread="2.11"/>
                    <measurement group_id="B3" value="6.26" spread="2.04"/>
                    <measurement group_id="B4" value="6.04" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Weight Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.40" spread="1.93"/>
                    <measurement group_id="B2" value="3.29" spread="2.10"/>
                    <measurement group_id="B3" value="3.18" spread="2.12"/>
                    <measurement group_id="B4" value="3.32" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISDM-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.32" spread="14.11"/>
                    <measurement group_id="B2" value="54.54" spread="15.66"/>
                    <measurement group_id="B3" value="58.65" spread="15.53"/>
                    <measurement group_id="B4" value="55.89" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Smoking Abstinence at 12 Months</title>
        <description>Prolonged Abstinence is defined as no smoking from the quit date to 12 Months post quit date.</description>
        <time_frame>From quit date to 12 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Bupropion</title>
            <description>Smokers in varenicline + bupropion took 0.5 mg varenicline once per day for the first three days and 0.5 mg bid (am and pm) for the next 4 days. They also took 150 mg bupropion (SR once per day for the first 3 days followed by 150mg bid for the next 4 days. From week 2-12 smokers in the VB group will take 1mg of varenicline and one active 150 mg bupropion tablet twice per day.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline</title>
            <description>Smokers in varenicline group took took 0.5 mg varenicline once per day for the first three days and 0.5 mg bid (am and pm) for the next 4 days. They also took a matching bupropion placebo on the same schedule as those in the varenicline + bupropion group. From week 2-12, smokers in the varenicline group took 1mg of varenicline and one bupropion matching placebo twice per day.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Smokers in the placebo group took a matching varenicline and bupropion placebos on the same schedule as the varenicline group took varenicline and the bupropion group took bupropion, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Abstinence at 12 Months</title>
          <description>Prolonged Abstinence is defined as no smoking from the quit date to 12 Months post quit date.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Varenicline + Bupropion</title>
          <description>Smokers in varenicline + bupropion took 0.5 mg varenicline once per day for the first three days and 0.5 mg bid (am and pm) for the next 4 days. They also took 150 mg bupropion (SR once per day for the first 3 days followed by 150mg bid for the next 4 days. From week 2-12 smokers in the VB group will take 1mg of varenicline and one active 150 mg bupropion tablet twice per day.</description>
        </group>
        <group group_id="E2">
          <title>Varenicline</title>
          <description>Smokers in varenicline group took took 0.5 mg varenicline once per day for the first three days and 0.5 mg bid (am and pm) for the next 4 days. They also took a matching bupropion placebo on the same schedule as those in the varenicline + bupropion group. From week 2-12, smokers in the varenicline group took 1mg of varenicline and one bupropion matching placebo twice per day.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Smokers in the placebo group took a matching varenicline and bupropion placebos on the same schedule as the varenicline group took varenicline and the bupropion group took bupropion, respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chest pain-cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tachycardia/Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Flashing lights</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection and infestation - Strep Throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infection and infestation - Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders-other: uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delerium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Depressive Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tachycardia/Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Earache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders, other-excessive thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Flashing lights</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>eye disorders, other-eye twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood in Stool</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cecal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gallbladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastro-esophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders, other-softer stools</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders, other-increased salivation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Appetite, decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Appetite, increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chest Pain - non cardiac</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Face Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>General Disorders and administration site conditions - Other, Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions, other -blood from throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, feeling speedy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Elevated GGT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Investigations - Increased Alcohol Consumption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Investigations, Other - Specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vascular disorders, other-hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy, Seasonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Immune system disorders - Shingles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gum infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infection and infestation - Other - swollen lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infection and infestation - Strep Throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infection and infestation - Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infections &amp; infestations, other-mycobacterium avium complex)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infections and infestations, other-fever blisters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infections and infestations, other-infection of R hand</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pharyngitis - bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations-other (abnormal EKG)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders &amp; administration site conditions - Diaphoresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders, other-low B12 levels</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Inflammation Gluteus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased lumbar spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>PERIPHERAL EDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Plantar Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neoplasms benign, malignant, and unspecified (incl cysts &amp; polyps) - other uterine fibroids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neoplasms, benign, malignant, &amp; unspecified, (incl cysts &amp; polyps) other-spot on cervix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nervous System disorders, other - Somniloquy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nervous system disorder other-jittery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nervous system disorder, other-feeling heart beating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nervous system disorder, other-headrushes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nervous system disorders, other-Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nervous system disorders, other-lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neurology - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Olfactory nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Slurred Speech</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anxiety symptoms</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Depressive Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders, other-emotional lability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, Self-Injurious Behavior</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - other, calmness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders other-altered mental state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders other-psychomotor retardation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders, other- panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders, other-pressured speech</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders, other-Nicotine Dependence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders-other (crying)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>other Sleep Disturbances</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders-other hematospermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal calculi</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Reproductive system and breast disorders other - Endometrial Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Reproductive system and breast disorders-other: uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Increased Coughing</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, mucopurulent sputum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other-Heavy Breathing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic, &amp; mediastinal disorders, other-exacerbation of COPD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical Procedures - Other, Eye Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures - Other, Eye Surgery (II)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures - Other, Eye Surgery (III)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures - Other, exploratory endoscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures - Other, tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures - Tonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures - back surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures -other, biopsy of prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures, other-removal of facial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures, other-Removal of cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures, other-root canal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Superficial thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vascular disorder, other-sweating</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul M. Cinciripini, BS,MS,PHD/Chair, Behavioral Science</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 745-1868</phone>
      <email>pcinciri@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

